SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy

Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD) worldwide. Glycemic and blood pressure (BP) control are important but not sufficient to attenuate the incidence and progression of DN. Sodium–glucose cotransporter (SGLT) 2 inhibitors are a new class of glucose-lowering age...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawanami, Daiji, Matoba, Keiichiro, Takeda, Yusuke, Nagai, Yosuke, Akamine, Tomoyo, Yokota, Tamotsu, Sango, Kazunori, Utsunomiya, Kazunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454992/
https://www.ncbi.nlm.nih.gov/pubmed/28524098
http://dx.doi.org/10.3390/ijms18051083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454992/
https://www.ncbi.nlm.nih.gov/pubmed/28524098
http://dx.doi.org/10.3390/ijms18051083

Ejemplares similares